IPERION (IPR) H1 2025 earnings summary

Executive summary

• Net loss attributable to shareholders was $363,730 for the six months ended 30 September 2024, an improvement from a $462,614 loss in the same period last year.

• No sales income was recorded during the period; cost improvements stemmed from lower outsourced manufacturing expenses and reduced administrative costs.

• Ongoing international efforts to promote Pathoglaze, with user trials and expanded R&D to increase market potential.

Financial highlights

• Net loss for the period was $363,730, compared to $462,614 in the prior year.

• Administrative expenses decreased by $14,715 year-over-year.

• Cash and cash equivalents at period end were $86,796, down from $168,647 at March 2024.

• Net cash outflow from operating activities was $268,040, improved from $370,787 outflow in the prior year.

• Basic and diluted loss per share was (0.071) cents, compared to (0.090) cents year-over-year.

Outlook and guidance

• Continued focus on building awareness and adoption of Pathoglaze, with ongoing user trials and R&D to expand applications and market size.

• Updates on material developments will be provided as they arise.